ImmVirX Poster Presentations on Preclinical and Clinical Programs at AACR Annual Meeting, Chicago
Melbourne, Australia 27 March 2025 – ImmVirX Pty Limited, a life sciences company focused on developing next-generation, receptor targeted oncolytic RNA immunotherapies to transform outcomes for patients with some of the most prevalent and challenging cancer types, will present two posters at the American Association for Cancer Research (AACR) Annual Meeting 2025, taking place April […]
